Skip to main content
Erschienen in: Strahlentherapie und Onkologie 9/2013

01.09.2013 | Original article

Glycolysis-related gene induction and ATP reduction during fractionated irradiation

Markers for radiation responsiveness of human tumor xenografts

verfasst von: Dr. K. Goetze, S.S. Meyer, A. Yaromina, D. Zips, M. Baumann, W. Mueller-Klieser

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Lactate was previously shown to be a prognostic but not a predictive pre-therapeutic marker for radiation response of tumor xenografts. We hypothesize that metabolic changes during fractionated irradiation may restrict the predictiveness of lactate regarding tumor radiosensitivity.

Materials and methods

Tumor xenografts were generated in nude mice by implanting 4 head and neck squamous cell carcinoma lines with different sensitivities to fractionated irradiation. Tumors were irradiated with up to 15 fractions of 2 Gy over a period of 3 weeks, and ATP and lactate levels were measured in vital tumor areas with induced metabolic bioluminescence imaging. Corresponding changes in mRNA expression of glycolysis-related genes were determined by quantitative RT-PCR.

Results

Lactate content decreased significantly in 3 out of 4 cell lines in the course of irradiation showing no correlation with cell line-specific radiosensitivity. Radiation-induced changes in ATP levels and glycolysis-related mRNA expression, however, only occurred in radiosensitive or intermediately radioresistant xenografts, whereas these parameters remained unchanged in radioresistant tumors.

Conclusion

Sensitivity-related differences in the transcriptional response of tumors to radiotherapy may be exploited in the clinic for better individualization of tumor treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Altenberg B, Greulich KO (2004) Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84:1014–1020PubMedCrossRef Altenberg B, Greulich KO (2004) Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84:1014–1020PubMedCrossRef
2.
Zurück zum Zitat Bernier J, Horiot JC (2012) Altered-fractionated radiotherapy in locally advanced head and neck cancer. Curr Opin Oncol 24:223–228PubMedCrossRef Bernier J, Horiot JC (2012) Altered-fractionated radiotherapy in locally advanced head and neck cancer. Curr Opin Oncol 24:223–228PubMedCrossRef
3.
Zurück zum Zitat Broggini-Tenzer A, Vuong V, Pruschy M (2011) Metabolism of tumors under treatment: mapping of metabolites with quantitative bioluminescence. Radiother Oncol 99:398–403PubMedCrossRef Broggini-Tenzer A, Vuong V, Pruschy M (2011) Metabolism of tumors under treatment: mapping of metabolites with quantitative bioluminescence. Radiother Oncol 99:398–403PubMedCrossRef
4.
Zurück zum Zitat Eicheler W, Zips D, Dorfler A et al (2002) Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. J Histochem Cytochem 50:197–204PubMedCrossRef Eicheler W, Zips D, Dorfler A et al (2002) Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. J Histochem Cytochem 50:197–204PubMedCrossRef
5.
Zurück zum Zitat Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899PubMedCrossRef Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899PubMedCrossRef
6.
Zurück zum Zitat Hirschhaeuser F, Sattler UG, Mueller-Klieser W (2011) Lactate: a metabolic key player in cancer. Cancer Res 71:6921–6925PubMedCrossRef Hirschhaeuser F, Sattler UG, Mueller-Klieser W (2011) Lactate: a metabolic key player in cancer. Cancer Res 71:6921–6925PubMedCrossRef
7.
Zurück zum Zitat Lee SC, Poptani H, Pickup S et al (2010) Early detection of radiation therapy response in non-Hodgkin’s lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging. NMR Biomed 23:624–632PubMedCrossRef Lee SC, Poptani H, Pickup S et al (2010) Early detection of radiation therapy response in non-Hodgkin’s lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging. NMR Biomed 23:624–632PubMedCrossRef
8.
Zurück zum Zitat Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E (2007) Energy metabolism in tumor cells. FEBS J 274:1393–1418PubMedCrossRef Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E (2007) Energy metabolism in tumor cells. FEBS J 274:1393–1418PubMedCrossRef
9.
Zurück zum Zitat Romero-Garcia S, Lopez-Gonzalez JS, Baez-Viveros JL et al (2011) Tumor cell metabolism: an integral view. Cancer Biol Ther 12:939–948PubMed Romero-Garcia S, Lopez-Gonzalez JS, Baez-Viveros JL et al (2011) Tumor cell metabolism: an integral view. Cancer Biol Ther 12:939–948PubMed
10.
Zurück zum Zitat Sattler UG, Meyer SS, Quennet V et al (2010) Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol 94:102–109PubMedCrossRef Sattler UG, Meyer SS, Quennet V et al (2010) Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol 94:102–109PubMedCrossRef
11.
Zurück zum Zitat Thews O, Zywietz F, Lecher B, Vaupel P (1999) Quantitative changes of metabolic and bioenergetic parameters in experimental tumors during fractionated irradiation. Int J Radiat Oncol Biol Phys 45:1281–1288PubMedCrossRef Thews O, Zywietz F, Lecher B, Vaupel P (1999) Quantitative changes of metabolic and bioenergetic parameters in experimental tumors during fractionated irradiation. Int J Radiat Oncol Biol Phys 45:1281–1288PubMedCrossRef
12.
Zurück zum Zitat Tozer G, Suit HD, Barlai-Kovach M et al (1987) Energy metabolism and blood perfusion in a mouse mammary adenocarcinoma during growth and following X irradiation. Radiat Res 109:275–293PubMedCrossRef Tozer G, Suit HD, Barlai-Kovach M et al (1987) Energy metabolism and blood perfusion in a mouse mammary adenocarcinoma during growth and following X irradiation. Radiat Res 109:275–293PubMedCrossRef
13.
Zurück zum Zitat Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033CrossRef Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033CrossRef
14.
Zurück zum Zitat Walenta S, Mueller-Klieser WF (2004) Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol 14:267–274PubMedCrossRef Walenta S, Mueller-Klieser WF (2004) Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol 14:267–274PubMedCrossRef
16.
Zurück zum Zitat Yaromina A, Krause M, Thames H et al (2007) Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol 83:304–310PubMedCrossRef Yaromina A, Krause M, Thames H et al (2007) Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol 83:304–310PubMedCrossRef
17.
Zurück zum Zitat Yaromina A, Kroeber T, Meinzer A et al (2011) Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 80:1205–1213PubMedCrossRef Yaromina A, Kroeber T, Meinzer A et al (2011) Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 80:1205–1213PubMedCrossRef
18.
Zurück zum Zitat Yaromina A, Zips D, Thames HD et al (2006) Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. Radiother Oncol 81:122–129PubMedCrossRef Yaromina A, Zips D, Thames HD et al (2006) Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. Radiother Oncol 81:122–129PubMedCrossRef
19.
Zurück zum Zitat Ziebart T, Walenta S, Sattler U et al (2010) Metabolite-induced bioluminescence for tumor prediction: detection of metabolites in tumors of the head and neck region. HNO 58:31–34PubMedCrossRef Ziebart T, Walenta S, Sattler U et al (2010) Metabolite-induced bioluminescence for tumor prediction: detection of metabolites in tumors of the head and neck region. HNO 58:31–34PubMedCrossRef
20.
Zurück zum Zitat Zips D, Boke S, Kroeber T et al (2011) Prognostic value of radiobiological hypoxia during fractionated irradiation for local tumor control. Strahlenther Onkol 187:306–310PubMedCrossRef Zips D, Boke S, Kroeber T et al (2011) Prognostic value of radiobiological hypoxia during fractionated irradiation for local tumor control. Strahlenther Onkol 187:306–310PubMedCrossRef
Metadaten
Titel
Glycolysis-related gene induction and ATP reduction during fractionated irradiation
Markers for radiation responsiveness of human tumor xenografts
verfasst von
Dr. K. Goetze
S.S. Meyer
A. Yaromina
D. Zips
M. Baumann
W. Mueller-Klieser
Publikationsdatum
01.09.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 9/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0371-9

Weitere Artikel der Ausgabe 9/2013

Strahlentherapie und Onkologie 9/2013 Zur Ausgabe

Mitteilungen der Fachgesellschaften

Mitteilungen der Fachgesellschaften

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.